clinical trial · NCT06723964
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
Advanced Solid TumorsAP505
brief summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors. The study will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for AP505.
started
Mar 30, 2023
primary completion
Oct 31, 2024
completion
Nov 30, 2025
last updated
Dec 9, 2024
official title
A Phase 1 Dose-Escalation Study to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of AP505 Injection, an Anti-PD-L1 and Anti-VEGF Bispecific Antibody, in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol